2025-12-16
ENA first public
ERC000011
ENA-CHECKLIST
Institute of Bioinformatics, Biocenter Medical University of Innsbruck
INSDC center name
public
INSDC status
ERS27310957
SRA accession
E-MTAB-16150:HEPG2_08_GW3965_2
Submitter Id
ArrayExpress
broker name
HepG2
cell line
hepatocyte
cell type
not collected
collection date
human
common name
Protocols: HepG2 cell line was ordered from ATCC (HB-8065) and cultured. Cells were harvested directly from cell culture and no dissection was perormed. HepG2 cells were cultivated in DMEM (Gibco, 41965) containing 10% FBS (Gibco, 10500064) and 1% penicillin/streptomycin (Gibco, 15140122) Cells were treated with treated with GW3965 (5µM), GW4064 (5 µM) alone or combined with mTORC1 inhibitor Torin 1 (TOI), or combined with glucose/glutamine starved media (GLUST). DMSO with final concentration of 0.1% (v/v) was used as control treatment.  RNA was extracted using Trizol reagent (Invitrogen, 15596026) according to the manufacturer's instructions. QuantSeq 3’ mRNA library preparation kit (Lexogen) according to manufacturer’s instructions.
description
adolescent
developmental stage
hepatocellular carcinoma
disease
wild type genotype
genotype
not collected
geographic location (country and/or sea)
not applicable
isolate
Homo sapiens
organism
Homo sapiens
organism
liver
organism part
Homo sapiens
scientific_name
DMEM, 10% FBS, 1% penicillin/streptomycin
stimulus
HEPG2_08_GW3965_2
title